Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats

Keiko Miyake(Tokushima University), Saburo Sone(Io Therapeutics (United States)), Chiyuki Suzuka(Tokushima University), Shino Yuasa(Tokushima University), Yoshinori Aono(Tokushima University), Kenji Tani(Tokushima University), Yuko Toyoda(Tokushima University), Masaki Hanibuchi(Tokushima University), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Jun Kishi(Tokushima University), Toshifumi Tezuka(Tokushima University), Yasuhiko Nishioka(Tokushima University)
The Journal of Medical Investigation
January 1, 2012
10.2152/jmi.59.174
Cited by 18

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134
Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer
|Cancer Research|2005|124